WealthPlan Investment Management LLC Has $17.12 Million Stake in AbbVie Inc. $ABBV

WealthPlan Investment Management LLC lowered its stake in shares of AbbVie Inc. (NYSE:ABBV) by 5.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,927 shares of the company’s stock after selling 3,876 shares during the quarter. AbbVie comprises approximately 1.1% of WealthPlan Investment Management LLC’s investment portfolio, making the stock its 21st biggest position. WealthPlan Investment Management LLC’s holdings in AbbVie were worth $17,117,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA bought a new stake in AbbVie during the second quarter worth about $25,000. Evolution Wealth Management Inc. bought a new position in AbbVie in the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie in the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $39,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on ABBV. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Guggenheim raised their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. UBS Group reissued a “neutral” rating on shares of AbbVie in a research note on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $246.89.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a three‑year voluntary agreement with the U.S. administration that exempts the company from tariffs and future pricing mandates while committing to major U.S. investment — a headline that reduces policy/regulatory uncertainty and signals long‑term U.S. capital deployment. Read More.
• Positive Sentiment: AbbVie signed an exclusive global licensing deal (up to ~$5.6B) with RemeGen for RC148, a PD‑1/VEGF bispecific — this meaningfully expands AbbVie’s oncology pipeline and long‑term growth optionality. Read More.
• Positive Sentiment: AbbVie is buying a drug‑delivery system and Arizona manufacturing facility from West Pharmaceutical and is investing in U.S. manufacturing (including a reported $175M plant spend) — supports supply chain control and the company’s U.S. investment pledge. Read More.
• Neutral Sentiment: AbbVie joined peers in urging FDA updates to post‑approval change rules — could improve manufacturing flexibility but is a regulatory/industry‑wide request with uncertain timing. Read More.
• Neutral Sentiment: A Phase 2 bipolar depression study (ABBV‑932) reached completion — a development milestone that requires readouts for directional impact. Read More.
• Negative Sentiment: Under the U.S. deal AbbVie agreed to provide lower prices in Medicaid (and expand affordable offerings) — a meaningful concession that could weigh on near‑term revenue and margins for affected products. Read More.

AbbVie Price Performance

Shares of NYSE ABBV opened at $220.51 on Wednesday. The company has a 50 day simple moving average of $226.84 and a 200 day simple moving average of $216.04. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a market cap of $389.72 billion, a PE ratio of 167.05, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s payout ratio is currently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.